CC-486 and Venetoclax for Acute Myeloid Leukemia
Primary Objective
To determine the maximum tolerated or recommended dose of CC-486 in combination with venetoclax
Details
Age
Adult
Type of Study
Treatment
Locations
Lone Tree Medical Center
University of Colorado Hospital
Principal Investigator
Daniel Pollyea, MD, MS
Study ID
Protocol Number: 20-1319
More information available at ClinicalTrials.gov: NCT05287568
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers